Study of Adalimumab or Placebo in Patients With Mild to Moderate COVID-19 (COMBAAT) (COMBAAT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT04705844

Recruitment Status : Withdrawn (study withdrawn prior to screening subjects)

First Posted : January 12, 2021

Last Update Posted : March 3, 2022

View this study on Beta.ClinicalTrials.gov

Sponsor:

Collaborators:

Pharm-Olam, LLC

Chemical, Biological, Radiological, and Nuclear Medical

Information provided by (Responsible Party):

Ology Bioservices

Study Details
Tabular View
No Results Posted
Disclaimer
How to Read a Study Record

No Study Results Posted on ClinicalTrials.gov for this Study

Study was withdrawn before participants were enrolled.

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Withdrawn
Estimated Primary Completion Date :	September 2022
Estimated Study Completion Date :	September 2022

To Top